A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

about

An 18F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent.

P2860

Q55326030-312392A9-504F-4B81-8918-CFEA0F8DB563

P2860

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

Item

http://www.wikidata.org/entity/Q52430620

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

@en

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

@nl

type

Item

label

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

@en

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

@nl

prefLabel

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

@en

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

@nl

P1476

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

@en

P2093

Austin Pantel

http://www.w3.org/2001/XMLSchema#string

Chi-Chang Weng

http://www.w3.org/2001/XMLSchema#string

Chia-Ju Hsieh

http://www.w3.org/2001/XMLSchema#string

Daniel A Pryma

http://www.w3.org/2001/XMLSchema#string

David A Mankoff

http://www.w3.org/2001/XMLSchema#string

Erin Schubert

http://www.w3.org/2001/XMLSchema#string

Fiona Simpkins

http://www.w3.org/2001/XMLSchema#string

Harrison Winters

http://www.w3.org/2001/XMLSchema#string

Hyoung Kim

http://www.w3.org/2001/XMLSchema#string

Kuiying Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity

Cancer statistics, 2016

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

P31

scholarly article

P356

10.1172/JCI97992

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Catherine Hou

P577

2018-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29509546

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5919879

http://www.w3.org/2001/XMLSchema#string

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

about

P2860

P2860

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P921

P932